WE ARE ENDECE
ENDECE, LLC is a privately held biopharmaceutical company at the forefront of new drug discovery and development. Our library of proprietary compounds, invented and owned by ENDECE, was designed to stop disease by up-regulating specific biological pathways to stimulate a biological response for a gain of function. We focus on diseases whose treatment options are limited or non-existent and whose causes may not be well understood including multiple sclerosis (MS) and Alzheimer’s disease.
ENDECE was founded in 2006 and is headquartered in Mequon, Wisconsin.
A small molecule therapy for MS patients appears to override inhibitors of oligodendrogenesis to induce remyelination. Presented by Dr. Steven H. Nye and Dr. James G. Yarger, of ENDECE, LLC, on September 15, 2016 at ECTRIMS 2016 in London, U.K.read more
ENDECE to Present Data at the 2016 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress
ENDECE will present “A small molecule therapy for MS patients appears to override inhibitors of oligodendrogenesis to induce remyelination” during a poster session at the 2016 European Committee for Treatment of Research in Multiple Sclerosis Congress (ECTRIMS) in London, United Kingdom.read more